Skip to main content

Table 7 Strong positive expresssion of p110 isforms and pAKT in 60 patients with DLBCLs by IHC

From: Frequent copy number variations of PI3K/AKT pathway and aberrant protein expressions of PI3K subunits are associated with inferior survival in diffuse large B cell lymphoma

   p110α P value p110β P value p110δ P value p110γ P value pAKT P value
Total no. of patients 60           
Age, years           
<60 y 36 12 (33.3) 0.037 10 (27.8) 0.639 12 (33.3) 0.068 7 (19.4) 1.000 7 (19) 0.293
≥60 y 24 4 (16.7)   5 (20.8)   3 (12.5)   4 (16.7)   2 (8.3)  
Sex            
 Male 39 7 (17.9) 0.153 9 (23.1) 0.762 11 (28.2) 0.435 7 (17.9) 1.000 7 (17.9) 0.473
 Female 21 9 (42.9)   6 (28.6)   4 (19.0)   4 (19.0)   2 (9.5)  
Primary site           
 node 54 14 (25.9) 0.653 14 (25.9) 1.000 14 (25.9) 1.000 8 (14.8) 0.069 8 (14.8) 1.000
Perpheral node 6 2 (33.3)   1 (26.7)   1 (16.7)   3 (50.0)   1 (16.6)  
B symptoms           
 Absence 37 10 (27.0) 0.936 10 (27.0) 0.764 11 (29.7) 0.283 6 (16.2) 0.734 4 (10.8) 0.284
 Presence 23 6 (26.1)   5 (21.7)   4 (17.4)   5 (21.7)   5 (21.7)  
Bulky disease           
<10 cm 47 11 (23.4) 1.000 13 (27.7) 0.561 12 (25.5) 1.000 8 (17.0) 0.552 7 (14.9) 1.000
≥10 cm 4 1 (25.0)   1 (0)   1 (25.0)   1 (25.0)   0 (0)  
Performance status          
 ECOG 0-1 50 13 (26.0) 1.000 13 (26.0) 0.965 12 (24.0) 1.000 9 (18.0) 0.571 8 (16) 1.000
 ECOG 2-4 4 1 (25.0)   1 (25.0)   1 (25.0)   1 (25.0)   0 (0)  
LDH            
<2*insitutioal ULN 30 9 (30.0) 0.445 11 (36.7) 0.133 9 (30.0) 0.445 7 (23.3) 0.483 6 (20) 0.277
>2*insitutioal ULN 24 5 (20.8)   4 (16.7)   5 (20.8)   3 (12.5)   2 (8.3)  
Extranodal site           
≤1 50 13 (26.0) 1.000 14 (28.0) 1.000 13 (26.0) 1.000 9 (18.0) 0.571 8 (16) 1.000
>1 4 1 (25.0)   1 (25.0)   1 (25.0)   1 (25.0)   0 (0)  
Stage            
I/II 29 5 (17.2) 0.077 8 (27.6) 0.904 10 (34.5) 0.168 4 (13.8) 0.307 4 (13.8) 1.000
III/IV 23 9 (39.1)   6 (26.1)   4 (17.4)   6 (26.1)   4 (17.4)  
IPI            
 0-1 30 10 (33.3) 0.142 11 (36.7) 0.087 11 (36.7) 0.037 5 (16.7) 1.000 6 (20) 0.269
 2-5 25 4 (16.0)   4 (16.0)   3 (12.0)   5 (20.0)   2 (8)  
Pathological type          
 GCB 26 4 (15.4) 0.084 6 (23.1) 0.764 4 (15.4) 0.133 3 (11.5) 0.320 4 (15.4) 1.000
 non-GCB 34 12 (35.3)   9 (26.5)   11 (32.4)   8 (23.5)   5 (14.7)  
  1. DLBCL diffuse large B-cell lymphoma, GCB germinal center B cell, IPI international prognostic index, LDH lactate dehydrogenase.